34 results about "CMV Pneumonia" patented technology

This invention discloses a method for preparing a bivalent inactivated vaccine against bovine Pasteurella multocida type A and B and hemolytic Mansicular disease, belonging to the field of vaccine technology. The invention involves isolating capsular serum Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease; separately expanding the culture of these bacteria, then inactivating and concentrating the bacterial suspensions, and resuspending them in PBS to prepare bacterial suspensions; and finally, mixing the Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease suspensions with aluminum hydroxide adjuvant to prepare the inactivated vaccine. This invention provides simultaneous prevention of two diseases—bovine fibrinous purulent pneumonia and bovine hemorrhagic septicemia—as well as bovine Mansicular disease through vaccine immunization. The vaccine demonstrates good safety, stable immunization efficacy, and a long duration of immunity.

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

The application discloses application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. A preparation method of the aloe oral liquid comprises the following steps: after fresh aloe leaves are washed and peeled, the fresh aloe leaves are scraped to prepare fresh aloe gel; the fresh aloe gel liquid is placed in a light reaction tank, and is subjected to blue light, red light and no light alternately under low-temperature conditions; the fresh aloe gel after light treatment is pumped into a decocting and concentrating tank, and is concentrated to a supernatant with a density of 1.10 kg / m 3 1.2 kg / m 3 between, is filled and sealed after cooling, and is sterilized to obtain the aloe oral liquid. The application promotes clinical indications of fresh aloe leaves, provides a new drug selection for clinical treatment of acute viral pneumonia, provides a technical reference for industrial production of fresh aloe leaf medicine products, and promotes inheritance and innovation of traditional Chinese medicines with clinical application as a foothold.

The application belongs to the field of intelligent medical treatment, and particularly relates to a method for constructing a refractory mycoplasma pneumoniae pneumonia prediction model and equipment. The method comprises the following steps: acquiring a baseline time data set and a follow-up time label of a mycoplasma pneumoniae patient; inputting the image data set into a lung blood vessel segmentation model to obtain a lung blood vessel network, obtaining a total lung blood vessel volume based on the lung blood vessel network, and obtaining a blood vessel volume of different cross-sectional areas based on a cross-sectional area of the lung blood vessel network; inputting a ratio of the blood vessel volume of different cross-sectional areas to the total lung blood vessel volume into a machine learning model to obtain a prediction label, and obtaining a refractory mycoplasma pneumoniae pneumonia prediction model after iterative optimization of the machine learning model based on a difference between the prediction label and the follow-up time label. The application segments a lung CT image to obtain a blood vessel network diagram, quantitatively obtains a percentage of a blood vessel volume of different thicknesses in a total lung blood vessel volume, and constructs a refractory mycoplasma pneumoniae pneumonia prediction model based on an innovative feature extraction method.

The application discloses a dandelion extract capable of neutralizing bacterial toxins and application thereof. The dandelion extract is mainly prepared by the following method: fresh dandelion juice is squeezed, the juice is collected, the juice is centrifuged, the supernatant is collected, the supernatant is ultra-filtered, and components capable of passing through a filter membrane with a molecular weight cut-off of 100 kD and incapable of passing through a filter membrane with a molecular weight cut-off of 3 kD are collected, namely the dandelion extract. The dandelion extract obtained by the application is natural in composition, free of toxic side effects and high in biological activity. Experimental evidence shows that the dandelion extract can protect host cells from attack by directly and specifically combining with toxins, effectively neutralizes the toxicity of bacterial toxins, and has effective prevention and treatment effects on diseases such as systemic bacterial infection, wound infection and bacterial pneumonia. Therefore, the dandelion extract can be used as a new type of anti-microbial and anti-infection functional material and applied to the fields of functional food, health products, medicines or functional cosmetics.

The application provides a biomarker and application for early detection of aspiration pneumonia. By detecting the biomarker, the defects of the current biomarker for aspiration pneumonia can be overcome, early detection of aspiration pneumonia can be realized, early intervention and preventive measures can be carried out, and the death caused by aspiration pneumonia can be greatly reduced.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The application of CCR2 / CCR5 inhibitor in the preparation of drugs for treating immune checkpoint inhibitor associated pneumonia and products belong to the field of biological medicine technology. The technical problem to be solved is the new application of CCR2 / CCR5 inhibitor in the preparation of drugs for treating pneumonia, and the treatment effect of immune checkpoint inhibitor associated pneumonia is better than that of single inhibitor. The technical solution is the application of CCR2 / CCR5 inhibitor in the preparation of drugs for treating pneumonia.

The application discloses a drug delivery system targeting lung alveolus microenvironment oxidation and reduction as well as a preparation method and application thereof, and comprises nanoparticles self-assembled by amphiphilic GSH-(oxi)PEI-PCL polymers, wherein the nanoparticles load fat-soluble drugs or fluorescent dyes, GSH in the amphiphilic GSH-(oxi)PEI-PCL polymers is connected with (oxi)PEI-PCL through a disulfide bond, and the (oxi)PEI-PCL is PEI-PCL subjected to partial oxidation. The pharmacodynamic test result shows that the drug delivery system can realize passive targeting aggregation of drugs in a lesion and microenvironment oxidation and reduction sensitive distribution, meanwhile, the drug delivery system shows an antioxidation effect in a lesion microenvironment and intracellular, realizes more accurate drug distribution effect and in-vivo treatment effect, and provides a new drug route for treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury.

This invention provides an antibacterial and anti-adhesion double-balloon tracheostomy cannula and its preparation method. The invention involves constructing a coating material co-loaded with a newly developed tetradecyl antibacterial agent and chondroitin sulfate on both the cannula's surface and inner wall. This coating possesses both excellent hydrophilicity and strong antibacterial properties. The hydrophilicity makes it difficult for secretions to adhere; the antibacterial properties kill bacteria through contact, minimizing the development of drug resistance; and the anti-adhesion properties reduce the basis for biofilm formation. These three properties work synergistically to achieve full-chain protection from the "source" to the "process," significantly reducing the risk of luminal obstruction and VAP (ventilator-associated pneumonia), while also reducing the frequency of suctioning and mucosal damage, thus improving patient comfort.

The application discloses application of chelerythrine combined with polymyxin E in inhibition of polymyxin E drug-resistant bacteria, and the polymyxin E drug-resistant bacteria are mcr positive bacteria. Experiments prove that chelerythrine can inhibit (such as mcr-1 positive escherichia coli ZJ807, mcr-8 positive klebsiella pneumoniae KP91 and mcr-9 positive salmonella SLM183) in cooperation with polymyxin E, and can reduce the use amount of polymyxin E and reverse the drug resistance to polymyxin E. Chelerythrine can restore the inhibitory effect of polymyxin E on the polymyxin E drug-resistant bacteria. The application has important application value.

The invention belongs to the technical field of microorganisms, and particularly relates to rabbit source D-type pasteurella multocida and application thereof. The preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: M 2024856. The strain induces cellulosic pneumonia, has an application value of constructing a rabbit pasteurellosis animal model, and has good immunogenicity, a whole-cell inactivated antigen can effectively stimulate immune response of a mouse body and induce generation of a high-level antibody, and the strain has the potential of being developed into a vaccine.

The invention provides an application of a serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia, and the serum exosome lncRNA is TTC9-DT, or TTC9-DT and ITGA2-AS1. The invention also provides an application of the serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia. By using the serum exosome lncRNA disclosed by the invention, the sensitivity, the specificity and the accuracy of immune checkpoint inhibitor-related pneumonia diagnosis can be remarkably improved, and compared with a clinical conventional non-specific blood index, the serum exosome lncRNA disclosed by the invention has a better diagnosis effect. In addition, detection can be carried out in a liquid biopsy mode, the method has the advantages of being minimally invasive, capable of achieving real-time monitoring and the like, a detection reagent is low in cost and high in universality, efficient clinical diagnosis and identification can be carried out, the early diagnosis rate is increased, and the method has high clinical application value and wide application prospects.

The invention belongs to the technical field of medicine. The invention discloses an application of forsythiaside A in preparation of a medicine for treating bacterial infectious pneumonia. The method comprises the following steps: firstly, establishing a model of mice bacterial infectious pneumonia caused by tracheal intubation instillation of Pseudomonas aeruginosa in vivo, and applying forsythiaside A to treat, so that the infection symptom of the model mice can be obviously relieved, and the lung inflammatory response can be effectively relieved. The method comprises the following steps: firstly, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, and then, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, so that after forsythiaside A is added, the damage of the macrophages can be effectively alleviated, and the number of infectious bacteria in cytoplasm can be reduced. Experimental results show that forsythiaside A can be effectively used for treating bacterial infectious pneumonia.

This invention belongs to the field of medical auxiliary prediction model construction technology. Current prediction models for refractory Mycoplasma pneumoniae pneumonia are all multimodal and rely on time-consuming experimental results, making them unsuitable for the clinical need to quickly determine the probability of having refractory Mycoplasma pneumoniae pneumonia. This invention proposes a method, device, medium, and program product for constructing a prediction model for refractory Mycoplasma pneumoniae pneumonia. By developing a Transformer-based deep learning framework, it achieves automated and efficient risk identification of RMPP using baseline non-contrast chest CT without additional examinations. Furthermore, a first prediction model is constructed based on the risk probability values ​​output by the Transformer-based deep learning framework, and a second prediction model is constructed based on the risk probability values ​​and six clinical data points. The predicted probabilities of each model show good consistency with the observed results.

This invention belongs to the field of traditional Chinese medicine application technology and provides an application of a traditional Chinese medicine composition in the treatment of radiation-induced pneumonia. The traditional Chinese medicine composition is made from bamboo sap and *Trifolium repens*; the mass ratio of bamboo sap to *Trifolium repens* is (1-10):(1-10). Radiation-induced pneumonia refers to lung inflammation caused by radiotherapy for malignant tumors of the chest. The traditional Chinese medicine composition provided by this invention has the effects of clearing heat and detoxifying, resolving phlegm and dissipating nodules. It has a simple composition and high safety, providing a new option for the treatment of radiation-induced pneumonia.

The invention provides an early warning method for PD-1 inhibitor immune-related pneumonia, which comprises the following steps: preprocessing acquired multi-omics data, conventional clinical data and CT image data of a PD-1 inhibitor subject to correspondingly obtain a multi-omics feature map, a clinical feature map and a CT image feature tensor; inputting the multiple omics feature maps, the clinical feature maps and the CT image feature tensor into a trained CNN-BNN model for feature extraction and pneumonia prediction to obtain a final disease time and a prediction result of disease probabilities of multiple time windows; and carrying out risk level judgment according to a prediction result, and outputting an early warning report and personalized treatment suggestions. According to the method, multi-dimensional information related to immune pneumonia is comprehensively captured by fusing multi-omics data, conventional clinical data and CT image data, and the accuracy and reliability of prediction are remarkably improved. The model is used for mining complex association in data, the prediction accuracy of the model is improved, and early warning and accurate prediction are realized.

The invention discloses application of polypeptide for inhibiting expression of inflammasome NLRP3 in preparation of pneumonia treatment drugs, and belongs to the technical field of biological medicines. Derived peptide is obtained based on a DTX4 protein functional domain, the peptide fragment is derived from an interaction region of DTX4 and RNA binding protein HuR, and the action mechanism of the peptide fragment is competitive binding with the HuR, so that the stabilizing effect of the HuR on mRNA of various inflammatory factors is blocked, the mRNA is promoted to be degraded, and expression and secretion of the inflammatory factors are inhibited from the level after transcription. The polypeptide disclosed by the invention has the potential of being developed into a novel anti-infectious pneumonia treatment medicine, and a brand new strategy is provided for treating bacterial infectious pneumonia.

This invention discloses a system and its application for differentiating different lung diseases in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

The invention relates to the technical field of biological medicines, and discloses a compound preparation of calcium phosphate-loaded bacterial membrane vesicles and application thereof. The preparation method comprises the following steps: preparing a single component, roughly purifying PA, KP and AB bacterial supernatant by adopting an ultracentrifugation method, and purifying to obtain bacterial membrane vesicles BMVs sourced from PA, KP and AB; caP is loaded into each BMVs through an ultrasonic method; after detecting to be qualified, freezing and storing at-80 DEG C for later use; the preparation of the compound preparation comprises the following steps: mixing the three single components in proportion, taking a PBS (Phosphate Buffer Solution) as a diluting medium, and carrying out sterile low-temperature stirring for mixing, so as to obtain the compound preparation. According to the composite preparation of the bacterial membrane vesicles loaded with the calcium phosphate and the application of the composite preparation, the composite preparation is wide in prevention coverage and can synchronously cope with infection of three hospital acquired pneumonia high-incidence pathogenic bacteria; the administration mode is convenient and efficient, multi-pathogen prevention is achieved through mixed preparation administration, and the clinical operation cost is reduced; the composition is good in component synergism, accurate and controllable in proportion and stable and reliable in prevention efficacy.

The invention provides an artemisia apiacea-scutellaria baicalensis carbon dot for treating influenza virus pneumonia and a preparation method thereof.The preparation method comprises the steps that artemisia apiacea and scutellaria baicalensis are adopted as raw materials according to the ratio of 1-3: 1-3, after standardized hydrothermal reaction and centrifugal filtration are conducted, high-acousto-optic-activity carbon dots are collected through a micro-fluidic chip, pulse ultrasound and sonoluminescence signal recognition screening technology, and the high-acousto-optic-activity carbon dots are obtained; the process is efficient and easy for large-scale production, and solves the problems of low extraction efficiency and non-uniform components of traditional Chinese medicines. The Artemisia apiacea-Scutellaria baicalensis carbon dot prepared by the method realizes antiviral and anti-inflammatory dual effects, can reduce influenza A virus load, regulate NLRP3 inflammation pathway, reduce inflammatory factor release and relieve lung pathological injury, has a curative effect superior to that of traditional decoction and single chemical medicine, and has more comprehensive intervention on systemic symptoms caused by virus infection.

The invention relates to a primer and probe combination for simultaneously detecting urinary tract klebsiella pneumoniae and drug-resistant genes through nested PCR (Polymerase Chain Reaction) and a kit of the primer and probe combination, which can solve the problem that the existing detection target lpxC of klebsiella pneumoniae is highly homologous with the sequence alignment of part of related bacteria (klebsiella oxytoca, enterobacter aerogenes and citrobacter freundii); based on the defect that a primer and probe combination designed by an existing target lpxC causes cross amplification of the bacteria and does not meet clinical requirements, and the situation that a combination of a drug-resistant gene mecA and klebsiella pneumoniae is not suitable for clinical scenes, by simultaneously identifying the klebsiella pneumoniae and common drug-resistant genes of the two bacteria, the drug-resistant genes of the two bacteria can be identified, and the drug-resistant genes of the two bacteria can be identified. The Klebsiella pneumoniae gene, namely a carbapenemase-producing drug-resistant gene KPC-2 and an extended-spectrum beta-lactamase-producing drug-resistant gene (ESBL) CTX-M-15, can be used for judging whether the Klebsiella pneumoniae is sensitive or drug-resistant Klebsiella pneumoniae and distinguishing specific drug-resistant phenotypes, so that more comprehensive and definite medication guidance can be provided for clinicians.

The invention discloses a kit for diagnosing inhalation pneumonia and a preparation method thereof, and belongs to the technical field of inhalation pneumonia detection. The kit for diagnosing the inhalation pneumonia comprises a PVC (polyvinyl chloride) bottom plate, a sample pad, a gold mark pad, a nanofiber membrane, a liquid absorption pad and a plastic card shell, a detection line 1, a detection line 2 and a quality control line are fixed on the nanofiber membrane; the detection line 1 and the detection line 2 consist of a colloidal gold labeled pepsinogen I antibody secondary antibody, a colloidal gold labeled pepsinogen II antibody secondary antibody; the preparation method comprises the following steps: under a nitrogen atmosphere, firstly, heating a chloroauric acid aqueous solution to be boiled, quickly adding a trisodium citrate aqueous solution, and boiling; cooling to room temperature, slowly adding an SH-PEG-COOH solution, reacting, standing overnight, centrifuging, washing, and adding a confining liquid to obtain a colloidal gold solution; the kit prepared by the invention has better accuracy and specificity and is convenient to operate.

The invention discloses an alveolar macrophage inhibitory natural product monomer and application thereof, and relates to the technical field of biological medicines. Seven natural product monomers including polyphyllin B, gentisic acid, catalpol, abscisic acid, aescin, ginsenoside and guaiacol are obtained through screening, and the menin / SETD2 interaction can be specifically inhibited. Experiments show that the monomers can inhibit expression of various inflammatory factors such as IL-1alpha, IL-1beta, IL-6 and the like induced by LPS in a dose-dependent manner; animal experiments prove that the monomers can obviously inhibit release of inflammatory factors induced by pathogens such as LPS and streptococcus pneumoniae, and can effectively relieve acute pneumonia and lung injury of mice. The provided natural product monomer is clear in target spot, specific in effect and broad in anti-inflammatory effect spectrum, and has important application prospects in treatment of cell / inflammatory factor storm related diseases caused by abnormal activation of alveolar macrophages.

The invention relates to the technical field of biological medicines, and discloses application of calcium phosphate-loaded bacterial membrane vesicles in preparation of a preparation for enhancing a bacterial pneumonia prevention effect. The bacterial membrane vesicles are derived from pseudomonas aeruginosa, klebsiella pneumoniae or acinetobacter baumannii; the extraction and purification of the bacterial membrane vesicles comprises the following steps: respectively selecting standard strains, namely pseudomonas aeruginosa, klebsiella pneumoniae and acinetobacter baumannii, and activating and culturing to a logarithmic phase; after the culture is completed, collecting bacterial supernatant through room-temperature centrifugation; and purifying the BMVs crude extract by using a gel filtration chromatography column. According to the application of the bacterial membrane vesicle loaded with the calcium phosphate in preparation of the preparation for enhancing the bacterial pneumonia prevention effect, the calcium phosphate is adopted as a broad-spectrum immunologic adjuvant, an immunologic enhancement system of the calcium phosphate and the bacterial membrane vesicle is efficient, universal and high in targeting specificity, corresponding pathogenic bacterium infectious pneumonia can be accurately prevented, and the preparation method is suitable for large-scale popularization and application. The prevention efficiency of the preparation is obviously improved; meanwhile, the preparation process is simple and mild, and the biological safety is high.

The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-DNABII antibodies or antigen-binding fragments thereof in an amount ranging from 10 to 150 mg / mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating biofilm-associated diseases or disorders, e.g., cystic fibrosis, ventilator-associated pneumonia, and acute exacerbations of chronic obstructive pulmonary disease or chronic bronchitis are also provided.

This invention relates to the field of biomedical technology, and more particularly to primer-probe combinations for broad-spectrum screening of common respiratory pathogens and their applications. Through screening and optimization, this invention has obtained a primer-probe combination for nucleic acid detection of respiratory pathogens for broad-spectrum screening of common acute respiratory infections and community-acquired pneumonia. The primer-probe combination described in this invention covers 18 respiratory pathogens and possesses advantages such as high accuracy, good specificity, strong anti-interference ability, good inclusiveness, high sensitivity, and superconductivity. Combined with fully enclosed single-tube PCR amplification, it can achieve parallel detection of 20 targets, greatly improving the early diagnosis of respiratory diseases with complex pathogen structures, and is of great significance for the prevention and treatment of infectious diseases.

The invention relates to the field of pathogen detection, and particularly discloses a sheep mycoplasmal pneumonia pathogen detection kit and application thereof. By designing a specific primer with high sensitivity and using a special DNA extraction reagent, high-quality mycoplasma DNA can be efficiently purified, a unique gene segment of PCR amplification targeted sheep mycoplasma is ensured, the problem of non-specific amplification or primer failure is effectively avoided, and the reliability of a detection result is ensured; the optimized cracking and purifying process can recover pathogen DNA from a small amount of disease materials to the maximum extent, pathogen loading capacity in a sample is low, the pathogen can be effectively detected, and the occurrence probability of false positive or false negative can be effectively reduced; meanwhile, the kit greatly shortens the detection time, is used for rapid diagnosis of a large number of clinical samples infected by mycoplasma pneumonia of sheep, and improves the detection efficiency.